Mucinous ovarian tumors are rare, so specific responses of this class of tumors to PD-L1 blockade are still developing, but the high expression of PD-L1 and known increase in TILs make it an interesting target for immunotherapy [17,19]. This evidence concerns the gene CD274 and ovarian neoplasm.